ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 1871-1888

  Cardoso, F ^a   Costa, A ^b,c   Norton, L ^d   Senkus, E ^e   Aapro, M ^f   Andre F ^g   Barrios, C H ^h   Bergh, J ⁱ   Biganzoli, L ^j   Blackwell, K L ^k   Cardoso, M J ^a   Cufer, T ^l   El Saghir, N ^m   Fallowfield, L ⁿ   Fenech, D ^o   Francis, P ^p   Gelmon, K ^q   Giordano, S H ^r   Gligorov, J ^s   Goldhirsch, A ^t   Harbeck, N ^u   Houssami, N ^v   Hudis, C ^d   Kaufman, B ^w   Krop, I ^x   Kyriakides, S ^y   Lin, U N ^x   Mayer, M ^z   Merjaver, S D ^aa   Nordstrom E B ^ab   Pagani, O ^ac   Partridge, A ^x   Penault Llorca, F ^ad   Piccart, M J ^ae   Rugo, H ^af   Sledge, G ^ag   Thomssen, C ^ah   van't Veer, L ^af   Vorobiof, D ^ai   Vrieling, C ^aj   West, N ^ak   Xu, B ^al   Winer, E ^x   more..

^a Champalimaud Cancer Center   (Portugal)

^b EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

^c European School of Oncology   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f Inst Multidisciplinaire d'Oncologie   (Switzerland)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j Sandro Pitigliani Medical Oncology Unit   (Italy)

^k DUKE CANCER INSTITUTE   (United States)

^l UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^m AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

ⁿ UNIVERSITY OF SUSSEX   (United Kingdom)

^o Europa Donna Malta   (Malta)

^p PETER MACCALLUM CANCER CENTRE   (Australia)

^q BRITISH COLUMBIA CANCER AGENCY   (Canada)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^s HÔPITAL TENON   (France)

^t EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^u Brustzentrum der Universität München   (Denmark)

^v UNIVERSITY OF SYDNEY   (Australia)

^w SHEBA MEDICAL CENTER   (Israel)

^x DANA FARBER CANCER INSTITUTE   (United States)

^y Europa Donna Cyprus   (Cyprus)

^z AdvancedBCorg   (United States)

^aa UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^ab Europa Donna Sweden and Bröstcancerföreningarnas Riksorganisation   (Sweden)

^ac ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^ad Jean Perrin Comprehensive Cancer Centre   (France)

^ae JULES BORDET INSTITUTE   (Belgium)

^af UNIVERSITY OF CALIFORNIA   (United States)

^ag INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^ah MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^ai Sandton Oncology Centre   (South Africa)

^aj Clinique et Fondation des Grangettes   (Switzerland)

^ak CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^al CANCER HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; CANCER GRADING; CLASSIFICATION; FEMALE; HUMAN; PATHOLOGY; PRACTICE GUIDELINE; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; GUIDELINES AS TOPIC; HUMANS; NEOPLASM GRADING; TREATMENT OUTCOME;

EID: 84921738804     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu385     Document Type: Article

References (130)

1. Cardoso, F., Metastatic breast cancer patients: the forgotten heroes!. The Breast 18 (2009), 271–272.
2. Largillier, R., Ferrero, J.-M., Doyen, J., et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 19 (2008), 2012–2019.
3. Andre, F., Slimane, K., Bachelot, T., et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22 (2004), 3302–3308.
4. Sundquist, M., Eriksson, Z., Tejler, G., et al. Trends in survival in metastatic breast cancer. Eur J Cancer, 8(3), 2010, 191 (abstract 453).
5. Foukakis, T., Fornander, T., Lekberg, T., et al. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat 130:2 (2011), 553–560.
6. Fiteni, F., Villanueva, C., Bazan, F., et al. Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions. The Breast 23 (2014), 165–169.
7. Hébert-Croteau, N., Brisson, J., Latreille, J., et al. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 22:18 (2004), 3685–3693.
8. Griggs, J.J., Culakova, E., Sorbero, M.E., et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25:18 (2007), 2522–2527.
9. Hassett, M.J., Hughes, M.E., Niland, J.C., et al. Selecting high priority quality measures for breast cancer quality improvement. Med Care 46:8 (2008), 762–770.
10. Cardoso, F., Costa, A., Norton, L., et al. 1st International consensus guidelines for advanced breast cancer (ABC1). The Breast 21:3 (2012), 242–252.
11. Metastatic breast cancer, Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. The Breast 16 (2007), 9–10.
12. Cardoso, F., Bedard, P.L., Winer, E.P., et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101 (2009), 1174–1181.
13. Pagani, O., Senkus-Konefka, E., Wood, W., et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: can metastatic breast cancer be cured?. J Natl Cancer Inst 102 (2010), 1–8.
14. Lin, N.U., Thomssen, C., Cardoso, F., et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: Surveillance, Staging, and Evaluation of Patients with Early-Stage and Metastatic Breast Cancer. The Breast 22:3 (2013), 203–210.
15. Guyatt, G., Gutterman, D., Baumann, M.H., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 129:1 (2006), 174–181.
16. Freeman, H.P., Patient navigation: a community centered approach to reducing cancer mortality. J Cancer Educ 21:1 suppl (2006), S11–S14.
17. Freund, K.M., Battaglia, T.A., Calhoun, E., et al. National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer 113 (2008), 3391–3399.
18. Hopkins, J., Mumber, M.D., Patient navigation through the cancer care continuum: an overview. J Oncol Pract 5:4 (2009), 150–1525.
19. Robinson-White, S., Conroy, B., Slavish, K.H., Rosenzweig, M., Patient navigation in breast cancer: a systematic review. Cancer Nurs 33:2 (2010), 127–140.
20. Ko, N.Y., Darnell, J.S., Calhoun, E., et al. Can patient navigation improve receipt of recommended breast cancer care? Evidence from the national patient navigation research program. J Clin Oncol, 2014 July 28 [Epub ahead of print].
21. Basch, E., The missing voice of patients in drug-safety reporting. N Engl J Med 362 (2010), 865–869.
22. Biganzoli, L., Wildiers, H., Oakman, C., et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Specialists (EUSOMA). Lancet Oncol 13 (2012), e148–e160.
23. Cardoso, F., Loibl, S., Pagani, O., et al. The EUSOMA recommendations for the management of young women with breast cancer. Eur J Cancer. 48:18 (2012), 3355–3377.
24. Partridge, A.H., Pagani, O., Abulkhair, O., et al. First international consensus guidelines for breast cancer in young women (BCY1). The Breast 23:3 (2014), 209–220.
25. Zimmermann, C., Swami, N., Krzyzanowska, M., et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 383:9930 (2014), 1721–1730.
26. Ganz, P.A., Yip, C.H., Gralow, J.R., et al. Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. The Breast 22:5 (2013), 606–615.
27. Cardoso, F., Bese, N., Distelhorst, S.R., et al. Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. The Breast 22:5 (2013), 593–605.
28. Silverman, R., Smith, L., Sundar, S., Is it my last christmas dinner?’ Survival of cancer patients having palliative chemotherapy during christmas period. BMJ Support Palliat Care, 4(Suppl 1), 2014, A56.
29. El Saghir, N.S., Adebamowo, C.A., Anderson, B.O., et al. Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. The Breast 20:Suppl 2 (2011), S3–S11.
30. Macdonald, S.M., Harris, E.E., Arthur, D.W., et al. ACR appropriateness criteria(R) locally advanced breast cancer. Breast J 17 (2011), 579–585.
31. Chia, S., Swain, S.M., Byrd, D.R., Mankoff, D.A., Locally advanced and inflammatory breast cancer. J Clin Oncol 26 (2008), 786–790.
32. Giordano, S.H., Update on locally advanced breast cancer. Oncologist 8 (2003), 521–530.
33. Yamauchi, H., Woodward, W.A., Valero, V., et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist 17 (2012), 891–899.
34. Brennan, M.E., Houssami, N., Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. The Breast 21 (2012), 112–123.
35. Slamon, D.J., Leyland-Jones, B., Shak, S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:11 (2001), 783–792.
36. Buzdar, A.U., Suman, V., Bernstam, F., ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Lancet Oncol, 14(13), 2013, 1317.
37. Ellis, M.J., Suman, V.J., Hoog, J., et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol 29 (2011), 2342–2349.
38. Cataliotti, L., Buzdar, A.U., Noguchi, S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the PRe-Operative ‘Arimidex’ Compared to Tamoxifen (PROACT) trial. Cancer 106 (2006), 2095–2103.
39. Ellis, M.J., Ma, C., Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 105:Suppl 1 (2007), 33–43.
40. Smith, I.E., Dowsett, M., Ebbs, S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005), 5108–5116.
41. Loibl, S., Blohmer, J.U., Fasching, P.A., et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular carcinoma of the breast. European Breast Cancer Conference, 2014 abstr. 398.
42. Masuda, N., Sagara, Y., Kinoshita, T., et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 13 (2012), 345–352.
43. Sinacki, M., Badzio, A., Welnicka-Jaskiewicz, M., et al. Pattern of care in locally advanced breast cancer: focus on local therapy. Breast 20 (2011), 145–150.
44. Dawood, S., Merajver, S.D., Viens, P., et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22 (2011), 515–523.
45. Cox, C., Holloway, C.M., Shaheta, A., et al. What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer?. Curr Oncol 20 (2013), 111–117.
46. Byrski, T., Gronwald, J., Huzarski, T., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28 (2010), 375–379.
47. Gronwald, J., Byrski, T., Huzarski, T., et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115 (2009), 359–363.
48. Byrski, T., Foszczynska-Kloda, M., Huzarski, T., et al. Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC). Breast Cancer Res, 14, 2012, R110.
49. WM Sikov DA Berry CM Perou. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Abstr. 2013 San Antonio Breast Cancer Symposium, San Antonio, USAS5-01.
50. von Minckwitz, G., Schneeweiss, A., Salata, C., et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple- negative and HER2 positive early breast cancer (GeparSixto). J Clin Oncol 15:7 (2014), 747–756.
51. Petrelli, F., Coinu, A., Borgonovo, K., et al. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 144:2 (2014), 223–232.
52. Alba, E., Chacon, J., Lluch, A., et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 136:2 (2012), 487–493.
53. Koshy, N., Quispe, D., Shi, R., et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19:3 (2010), 246–248.
54. Hemsell, D.L., Grodin, J.M., Brenner, P.F., et al. Plasma precursors of oestrogen II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 38 (1974), 476–479.
55. Handesman, D., Androgen Actions and Pharmacologic Uses, Endocrinology. 2001, WB Saunders, Philadelphia, 2232–2242.
56. Sousa, B., Moser, E., Cardoso, F., An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol 717 (2013), 71–83.
57. Nordman, I.C., Dalley, D.N., Breast cancer in men—should aromatase inhibitors become first-line hormonal treatment?. Breast J 4 (2008), 562–569.
58. Faneyte, I.F., Turgers, E.J., Zoetmulder, F.A., Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer, 80(5), 1997, 886.
59. Schwaibold, F., Fowble, B.L., Solin, L.J., et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys, 21, 1991, 299.
60. Skinner, H.D., Strom, E.A., Motwani, et al. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol 8 (2013), 13–22.
61. Müller, A.C., Eckert, F., Heinrich, V., et al. Re-surgery and chest wall re-irradiation for recurrent breast cancer: a second curative approach. BMC Cancer, 11, 2011, 197.
62. Kilburn, J.M., Kuremsky, J.G., Blackstock, A.W., et al. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol 110:3 (2014), 505–510.
63. Seiwer, T.Y., Salama, J.K., Vokes, E.E., The concurrent chemoradiation paradigm- general principles. Nat Clin Pract, 4(2), 2007, 86.
64. Wilson, G.D., et al. Biologic basis for combining drugs with radiation. Semin Radiation Oncol 16 (2006), 2–9.
65. Lawrence, T.S., et al. Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiation Oncol 7 (1997), 260–266.
66. Sawada, N., et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine in human cancer xenografts. Clin Cancer Res 5 (1999), 2948–2953.
67. Crane, C.H., et al. Is the therapeutic index better with gemcitabine-based chemotherapy than with 5-fluoruracil-based chemoradiation in locally advance pancreatic cancer?. Int J Radiat Oncol Biol Phys 52 (2002), 1293–1302.
68. Liebmann, J., et al. In vitro studies of taxol as a radiosensitizer in human cancer cells. J Natl Cancer Inst 86:6 (1994), 441–446.
69. Gonzales, J.E., et al. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuzimab and nimotuzumab in A431 cells. Cancer Biol Ther 13:2 (2012), 71–76.
70. Horton, J.K., et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase 2 trial. Int J Radiat Oncol Biol Phys 76:4 (2010), 998–1004.
71. Löser, D.A., et al. Sensitization to radiation and alkylating agents by inhibitors of poly (ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 9:6 (2010), 1775–1787.
72. Jones, E.L., Oleson, J.R., Prosnitz, L.R., et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol. 23 (2005), 3079–3085.
73. Vernon, C.C., Hand, J.W., Field, S.B., et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. Int J Radiat Oncol Biol Phys 35 (1996), 731–744.
74. Zagar, T.M., Higgins, K.A., Miles, E.F., et al. Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. Radiother Oncol 97 (2010), 535–540.
75. Borner, M., Bacchi, M., Goldhirsch, A., et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 12:10 (1994), 2071–2077.
76. Aebi, S., et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomized trial. Lancet Oncol 15:2 (2014), 156–163.
77. Robertson, J.F., Osborne, C.K., Howell, A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:2 (2003), 229–238.
78. Howell, A., Pippen, J., Elledge, R.M., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104:2 (2005), 236–239.
79. Chia, S., Gradishar, W., Mauriac, L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:10 (2008), 1664–1670.
80. Di Leo, A., Jerusalem, G., Petruzelka, L., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28:30 (2010), 4594–4600.
81. Johnston, S.R., Kilburn, L.S., Ellis, P., et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14:10 (2013), 989–998.
82. Gibson, L., Lawrence, D., Dawson, C., Bliss, J., Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev(4), 2009, CD003370.
83. Bonneterre, J., Thürlimann, B., Robertson, J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18 (2000), 3748–3757.
84. Nabholtz, J.M., Buzdar, A., Pollak, M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18 (2000), 3758–3767.
85. Milla-Santos, A., Milla, L., Portella, J., et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 26 (2003), 317–322.
86. Paridaens, R., Dirix, L., Lohrisch, C., et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14 (2003), 1391–1398.
87. Mouridsen, H., Gershanovich, M., Sun, Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003), 2101–2109.
88. Paridaens, R.J., Dirix, L.Y., Beex, L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26 (2008), 4883–4890.
89. Baselga, J., Campone, M., Piccart, M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:6 (2012), 520–529.
90. Yardley, D.A., Noguchi, S., Pritchard, K.I., et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30 (2013), 870–884.
91. Piccart, M., Hortobagyi, G.N., Campone, M., et al. Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. Eur J Cancer, 50(Suppl 3), 2014, S1.
92. Bachelot, T., Bourgier, C., Cropet, C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30:22 (2012), 2718–2724.
93. Gelmon, K.A., Boyle, F., Kaufman, B., et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER-2 metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol, 30, 2012 (Suppl: LBA671).
94. Pivot, X., Semiglazov, V., Zurawski, V., et al. CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients with HER2+ metastatic breast cancer, treated with lapatinib plus capecitabine versus trastzumab pluas capecitabine. Ann Oncol 23:Suppl 9 (2012), ixe1–ixe30.
95. Piccart-Gebhart, M., Holmes, A.P., Baselga, J., et al. First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol, 32(Suppl 5s), 2014 abstr LBA4.
96. Baselga, J., Cortes, J., Kim, S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366 (2012), 109–119.
97. Swain, S.M., et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Lancet Oncol, 14, 2013 (6): 461–471.
98. Cortés, J., Fumoleau, P., Bianchi, G.V., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:14 (2012), 1594–1600.
99. Blackwell, K.L., Miles, D., Gianni, L., et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol, 30, 2012 5s (suppl 15: abstr LBA1).
100. Verma, S., Miles, D., Gianni, L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 (2012), 1783–1791.
101. Wildiers, H., Kim, S.B., Gonzalez-Martin, A., et al. T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice. Presented at the European Cancer Congress, 2013 (abstr LBA15).
102. Dear, R.F., McGeechan, K., Jenkins, M.C., et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev(12), 2013, 008792.
103. Piccart-Gebhart, M.J., Burzykowski, T., Buyse, M., et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26:12 (2008), 1980–1986.
104. Stockler, M.R., Harvey, V.J., Francis, P.A., et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29:34 (2011), 4498–4504.
105. Blum, J.L., Barrios, C.H., Feldman, N., et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 136 (2012), 777–788.
106. Robert, N.J., Dieras, V., Glaspy, J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29 (2011), 1252–1260.
107. O'Shaughnessy, J.A., Blum, J., Moiseyenko, V., et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12 (2001), 1247–1254.
108. Brufsky, A.M., Hurvitz, S., Perez, E., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29 (2011), 4286–4293.
109. Talbot, D.C., Moiseyenko, V., Van Belle, S., et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86 (2002), 1367–1372.
110. Blum, J.L., Jones, S.E., Buzdar, A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 (1996), 485–493.
111. Blum, J.L., Dieras, V., Lo Russo, P.M., et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92 (2001), 1759–1768.
112. Miller, K.D., Chap, L.I., Holmes, F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005), 792–799.
113. Andersson, M., Lidbrink, E., Bjerre, K., et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA Study. J Clin Oncol 29 (2010), 264–271.
114. Burstein, H.J., Keshaviah, A., Baron, A.D., et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110:5 (2007), 965–972.
115. Cortes, J., O'Shaughnessy, J., Loesch, D., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:9769 (2011), 914–923.
116. Kaufman, P.A., Awada, A., Twelves, C., et al. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res, 72(24 Suppl), 2012 abstract S6–6).
117. Dominici, L., Najita, J., Hughes, M., et al. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat 129 (2011), 459–465.
118. Ly, B.H., Nguyen, N.P., Vinh-Hung, V., et al. Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit?. Breast Cancer Res Treat 119 (2010), 537–545.
119. Neuman, H.B., Morrogh, M., Gonen, M., et al. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter?. Cancer 116 (2010), 1226–1233.
120. Rashaan, Z.M., Bastiaannet, E., Portielje, J.E., et al. Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery. Eur J Surg Oncol 38 (2012), 52–56.
121. Ruiterkamp, J., Ernst, M.F., The role of surgery in metastatic breast cancer. Eur J Cancer 47:Suppl 3 (2011), S6–S22.
122. Nguyen, D.H., Truong, P.T., Alexander, C., et al. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?. Int J Radiat Oncol Biol Phys 84 (2012), 39–45.
123. Petrelli, F., Barni, S., Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol 29 (2012), 3282–3290.
124. Ruiterkamp, J., Voogd, A.C., Tjan-Heijnen, V.C., et al. SUBMIT: Systemic therapy with or without upfront surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation. BMC Surg, 12, 2012, 5.
125. Shien, T., Nakamura, K., Shibata, T., et al. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol 42 (2012), 970–973.
126. Badwe, R., Parmar, V., Hawaldar, R., et al. Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial. Cancer Res, 73(24 Suppl), 2013 S2-02.
127. Soran, A., Ozmen, V., Ozbas, S., et al. Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). Cancer Res, 73(24 Suppl), 2013 S2-03.
128. Thompson, A.M., Jordan, L.B., Quinlan, P., et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res, 12, 2010, R92.
129. Amir, E., Clemons, M., Purdie, C.A., et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 38 (2012), 708–714.
130. Foukakis, T., Åström, G., Lindström, L., et al. When to order a biopsy to characterise a metastatic relapse in breast cancer. Ann Oncol 23:Suppl 10 (2012), x349–x353.